Cancer Research | Penn Today

Penn researchers believe new potential gene therapy for glioblastoma brain cancer offers ‘a lot of hope’

Donald O’Rourke of the Perelman School of Medicine and colleagues have found that a dual-target CAR T cell therapy approach shows promise for slowing tumor growth in glioblastoma, an aggressive and fast-growing brain cancer.

Celebrity breast cancer announcements highlight rising rates in young women

Oluwadamilola Fayanju of the Perelman School of Medicine recommends that young women with breast cancer symptoms go to a center that’s experienced in breast imaging.

From no hope to a potential cure for a deadly blood cancer

Carl June of the Perelman School of Medicine discusses multiple myeloma.

Trials aim to make cancer relapse a thing of the past

At Penn Medicine, clinical trials are testing methods that may stop cancer from recurring.

6 min. read

Evidence of CAR T-cell therapy against cancers presented at U.S. conference

A study by researchers at Penn finds that that CAR T-cell therapy “shows promise for slowing tumor growth in a notoriously aggressive and fast-growing brain cancer.”

The human brain as though it is being scanned.

Dual-target CAR T-cell therapy slows growth of aggressive brain cancer

Researchers from Penn Medicine have demonstrated encouraging tumor reductions rarely seen in recurrent glioblastoma following phase I clinical trials.

3 min. read

Gilead’s CAR-T cell therapy shows promise in deadly brain cancer

A study led by Stephen Bagley of the Perelman School of Medicine found that a dual CAR-T cell treatment shrank tumors in 62% of patients with recurrent glioblastoma, a fatal brain cancer with few treatment options.

Trump suggests Biden’s cancer diagnosis was hidden from public

PIK Professor Ezekiel Emanuel comments on the prostate cancer diagnosis of former President Biden.

Promising inhibitor combination for hard-to-treat leukemia subtypes

Researchers from Penn Vet and other institutions have identified a novel inhibitor combination of molecules that induce terminal differentiation for the treatment of human non-APL subtypes of AML.

2 min. read

Dad able to look to future after biomarker testing, targeted drug therapy treat his Stage 4 cancer

Chris D’Avella of the Perelman School of Medicine says that are certain targetable mutations in tumors that drive the growth of non-smoking-related lung cancer.

Filters